Imiquimod for Melanoma
This trial studies the side effects and efficacy of imiquimod and pembrolizumab in treating patients with stage IIIB-IV melanoma.
- Metastatic Melanoma
- Cutaneous Melanoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the scale of participation in this research project?
"As of now, this study is not currently enrolling. It was initially published in December 2017 and last edited on October 7th 2022; however, there are 832 studies recruiting participants with stage IV cutaneous melanoma AJCC V6 and V7 as well as 978 trials utilizing Pembrolizumab actively seeking volunteers."
Are there any available openings for individuals seeking to join this clinical trial?
"This research project is not presently looking for new participants. It was first publicized on December 20th 2017 and most recently edited October 7th 2022. However, if you are searching for alternatives, 832 clinical trials with Stage IV cutaneous melanoma AJCC v6 & V7 are actively recruiting as well as 978 experiments using Pembrolizumab."
What other research has been conducted regarding the use of Pembrolizumab?
"At present, there are 978 clinical trials pertaining to Pembrolizumab in active progress and 127 of those studies have progressed past the second phase. Although numerous investigations are conducted out of Nashville, Tennessee, a total of 36006 research centres around the world are currently exploring this novel therapy."